Evidence map›Paper›PMID 29594039›Full record

ArticleFrontiers in oncology2018

Genetic Evidence for Early Peritoneal Spreading in Pelvic High-Grade Serous Cancer.

Jeremy Chien, Lisa Neums, Alexis F L A Powell, Michelle Torres, Kimberly R Kalli, Francesco Multinu, Viji Shridhar, Andrea Mariani

Abstract read
In one paragraph

Article in Frontiers in oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jeremy ChienDepartment of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, United States.
Lisa NeumsDepartment of Biostatistics, University of Kansas Medical Center, Kansas City, MO, United States.
Alexis F L A PowellDepartment of Biological Sciences, Emporia State University, Emporia, KS, United States.
Michelle TorresDepartment of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, United States.
Kimberly R KalliDivision of Medical Oncology, Mayo Clinic, Rochester, MN, United States.
Francesco MultinuDepartment of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, United States.
Viji ShridharDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States.
Andrea MarianiDepartment of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, United States.

Funding

Mentoring CoreP20GM103418 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Douglas E Wright · 2012 to 2026
$63.0M
NIGMS NIH HHS P20 GM103418
6 · The paper itself

Abstract

backgroundMost pelvic high-grade serous (HGS) carcinomas have been proposed to arise from tubal primaries that progress rapidly to advanced disease. However, the temporal sequence of ovarian and peritoneal metastases is not well characterized.

methodsTo establish the sequence of metastases, phylogenetic relationships among the ovarian and peritoneal carcinomas were determined from single-nucleotide variations (SNVs) in nine tumor regions from each patient with pelvic HGS carcinomas. Somatic SNVs from each tumor sample were used to reconstruct phylogenies of samples from each patient. Variant allele frequencies were used to reconstruct subclone phylogenies in each tumor sample.

resultsWe show that pelvic HGS carcinomas are highly heterogeneous, only sharing less than 4% of somatic SNVs among all nine carcinoma implants in one patient. TP53 mutations are found in all nine carcinoma implants in each patient. The phylogenetic analyses reveal that peritoneal metastases arose from early branching events that preceded branching events for ovarian carcinomas in some patients. Finally, subclone phylogenies indicate the presence of multiple subclones at each tumor implant and early tumor clones in peritoneal implants.

conclusionThe genetic evidence that peritoneal implants arose before or concurrently with ovarian implants is consistent with the emerging concept of the extra-ovarian origin of pelvic HGS cancer. Our results challenge the concept of stepwise spatial progression from the fallopian primary to ovarian carcinomas to peritoneal dissemination and suggest an alternative progression model where peritoneal spreading of early clones occurs before or in parallel with ovarian metastases.

Indexed as

cancer genomicsintratumor heterogeneityovarian cancersperitoneal spreadphylogenetic analysisprogression

Identifiers

PMID29594039
PMCPMC5858520

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.